Overview

• Global medtech leader's Q4 revenue rose 8%, beating analyst expectations

• Adjusted EPS for Q4 missed analyst expectations

• Company advances ongoing board of directors refreshment

Outlook

• Company expects full-year 2026 adjusted EPS between $1.85 and $2.05

• Baxter projects flat to 1% reported sales growth for 2026

• Company forecasts organic sales growth to be approximately flat in 2026

Result Drivers

• IV SOLUTIONS - Increased sales in Infusion Therapies & Technologies driven by strength in IV solutions

• ADVANCED SURGERY DEMAND - Strong global demand for Advanced Surgery products contributed positively to performance

• PRODUCT MIX IMPACT - Adjusted EPS decreased due to unfavorable product mix and non-recurring items

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 14 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Baxter International Inc is $21.50, about 3.5% below its February 11 closing price of $22.27

• The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nBw45mw77a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)